J. B. Dever, J. H. Ducom, and A. Ma, Engagement in care of high-risk hepatitis c patients with interferon-free direct-acting antiviral therapies, Dig Dis Sci, vol.62, pp.1472-1479, 2017.

C. Kim, T. Kerr, and K. Li, Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting, BMC Public Health, vol.29, p.270, 2009.

C. Metzig, J. Surey, and M. Francis, Impact of hepatitis C treatment as prevention for people who inject drugs is sensitive to contact network structure, Sci Rep, vol.7, p.1833, 2017.

P. Bruggmann, L. Falcato, and S. Dober, Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients, J Viral Hepat, vol.15, pp.747-752, 2008.

J. Grebely, M. Oser, L. E. Taylor, and G. J. Dore, Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels, J Infect Dis, vol.207, pp.19-25, 2013.

D. Salmon-ceron, J. Cohen, and M. Winnock, Engaging HIVHCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France), BMC Health Serv Res, vol.12, p.59, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00687514

L. E. Taylor, T. Swan, and G. V. Matthews, Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.57, pp.118-124, 2013.